Europe Human Insulin Market Size, Share & COVID-19 Impact Analysis, By Type (Analog Insulin, and Traditional Insulin), By Diabetes Type (Diabetes 1, and Diabetes 2), By Distribution Channel (Hospital Pharmacy, and Retail & Online Pharmacy), and Regional Forecast, 2023-2030

Europe is the second largest region in the global human insulin market. Europe human insulin market size is projected to grow at a CAGR of 1.5% during the forecast period. The global human insulin market is projected to grow from USD 18.7 billion in 2022 to USD 21.0 billion by 2030.

Rising product launches by key regional players have led to the introduction and improved access to cost-effective human insulin products in European countries. For instance, in March 2020, the ultra-rapid-acting insulin Lyumjev injection had received market authorization from the European Medicines Agency (EMA) in adults with type 1 diabetes.

Our report on the Europe human insulin market covers the following countries/regions – U.K., Germany, France, Italy, Spain, Scandinavia, and the rest of Europe.

LATEST TRENDS

Request a Free sample to learn more about this report.

Wider Adoption Among the Diabetic Population to Offer New Growth Opportunities

Human insulin awareness is increasing owing to the rising prevalence of diabetes and rising blood sugar levels among the population in Europe. Thus, rising awareness and the vast presence of cost-effective products by key players enhanced the adoption of human insulin therapy in the region, which drives market growth. Moreover, extensive presence and distribution channels for the supply of products by major regional players is further expected to aid in market growth.

• As per Sanofi's annual report estimates, in 2021, the Lantus (insulin glargine) insulin sales generated a revenue of USD 564.2 million in Europe.

DRIVING FACTORS

Greater Focus over Technologically Advanced Systems by Key Players to Accelerate Market Growth

Several players across Europe are focusing on increasing the production and introduction of new novel medicines owing to the high prevalence of diabetes. Also, many organizations are focusing on developing technologically advanced insulin products and delivery systems across developed countries. Thus, rising investments in R&D and commercialization in the development of human insulin products in the region, will propel the market share in the global market.

• In April 2022, in a diabetes tech trifecta, Abbott entered a partnership with Ypsomed and CamDiab for the development of an integrated automated insulin delivery system. The partnership has an initial focus on European countries.

RESTRAINING FACTORS

Rising Introduction of Biosimilar by Key Players to Hamper the Market Growth

The demand for alternative insulin products owing to high costs of existing traditional human insulins medications is rising among the population. Thus, several key players are now focusing on producing and launching insulin alternative biosimilars for diabetes care in the region. Therefore, the rising introduction of alternative insulin medications, such as biosimilar insulins, will restrain the market during the forecast period.

• In June 2020, Sanofi received authorization for marketing its insulin aspart biosimilar (Insulin aspart Sanofi) from the European Commission. The product became the first insulin aspart biosimilar to get approval in Europe.

KEY INDUSTRY PLAYERS

In terms of competitive landscape, Novo Nordisk A/S, Eli Lilly and Company, and Sanofi comprise most of the market share of the Europe region due to their robust product offerings, strong distribution network, and new product launches and approvals in the forecast period.

Other prominent players such as ADOCIA and B. Braun Melsungen AG are also leading the market due to rising R&D investments and strategic collaborations & partnerships among the players to increase their human insulin market share in Europe.

LIST OF KEY COMPANIES PROFILED:

• Novo Nordisk A/S (Denmark)


• Eli Lilly and Company (U.S.)


• Sanofi (France)


• B. Braun Melsungen AG (Germany)


• WOCKHARDT (India)


• ADOCIA (France)


• Biocon (India)


• BIOTON S.A. (Poland)


• Lupin (India)

KEY INDUSTRY DEVELOPMENTS:

• January 2023: Abbott partnered with Sanofi for the development of tools that combine the FreeStyle Libre technology with insulin dosing information from Sanofi’s diabetes care products. The collaboration will enable people with diabetes and healthcare professionals to take better treatment decisions around lifestyle, nutrition, and medication.


• August 2022: The Oralis project by Oramed received support from US FDA and the European EMA for the provision of additional support for a Phase III clinical trial of Oralis for confirming oral drug efficacy for the purpose of glycaemic control in type 2 diabetes patients.


• June 2021: Sanofi announced that the new Soliqua, a long-acting human insulin analog, showed improved blood sugar control without weight gain against premixed insulin.

REPORT COVERAGE

To gain extensive insights into the market, Request for Customization

The market report provides a detailed market analysis. It focuses on key aspects such as the launch of new products, technological advancements, and the prevalence of diabetes. Besides this, the report offers insights into the market trends and highlights key industry developments such as mergers, partnerships, and acquisitions and the impact of COVID-19 on the market. In addition to the above-mentioned factors, the report encompasses several factors that have contributed to the market growth over recent years.

Report Scope & Segmentation